Is ATAI or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Atai Beckley's net margin of -14,938.36%. Belite Bio's return on equity of -11.84% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -14,938.36% -88.30% -58.88% Belite Bio N/A -11.84% -11.62%

Which has better earnings and valuation, ATAI or LNTH?

Lantheus has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atai Beckley $4.09M 666.46 -$660.05M -$2.18 N/A Lantheus $1.54B 4.23 $233.56M $4.14 24.14

Is ATAI or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Atai Beckley's net margin of -14,938.36%. Lantheus' return on equity of 28.10% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -14,938.36% -88.30% -58.88% Lantheus 17.69% 28.10% 14.35%

This company has been marked as potentially delisted and may not be actively trading.

Atai Beckley (ATAI) Competitors

Compare

ATAI vs. RDY, AXSM, CRNX, BLTE, and LNTH

Should you buy Atai Beckley stock or one of its competitors? Atai Beckley's main competitors and comparable companies include Dr. Reddy's Laboratories (RDY), Axsome Therapeutics (AXSM), Crinetics Pharmaceuticals (CRNX), Belite Bio (BLTE), and Lantheus (LNTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Atai Beckley compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Atai Beckley (NASDAQ:ATAI) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

In the previous week, Dr. Reddy's Laboratories had 1 more articles in the media than Atai Beckley. MarketBeat recorded 1 mentions for Dr. Reddy's Laboratories and 0 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.25 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Overall Sentiment
Dr. Reddy's Laboratories	Neutral
Atai Beckley	Neutral

Dr. Reddy's Laboratories presently has a consensus price target of $1,450.00, indicating a potential upside of 11,724.19%. Atai Beckley has a consensus price target of $10.56, indicating a potential upside of 43.62%. Given Dr. Reddy's Laboratories' higher possible upside, equities research analysts clearly believe Dr. Reddy's Laboratories is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Atai Beckley's net margin of -14,938.36%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Atai Beckley	-14,938.36%	-88.30%	-58.88%

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 19.8% of Atai Beckley shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.86	$456M	$0.44	27.87
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A

Summary

Dr. Reddy's Laboratories beats Atai Beckley on 10 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Atai Beckley (NASDAQ:ATAI) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Axsome Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

Axsome Therapeutics currently has a consensus price target of $275.84, indicating a potential upside of 53.89%. Atai Beckley has a consensus price target of $10.56, indicating a potential upside of 43.62%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06

Axsome Therapeutics has a net margin of -24.68% compared to Atai Beckley's net margin of -14,938.36%. Atai Beckley's return on equity of -88.30% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Atai Beckley	-14,938.36%	-88.30%	-58.88%

Axsome Therapeutics has higher revenue and earnings than Atai Beckley. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	14.70	-$183.17M	-$3.75	N/A
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A

In the previous week, Axsome Therapeutics had 10 more articles in the media than Atai Beckley. MarketBeat recorded 10 mentions for Axsome Therapeutics and 0 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.25 beat Axsome Therapeutics' score of 0.01 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Overall Sentiment
Axsome Therapeutics	Neutral
Atai Beckley	Neutral

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Atai Beckley shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 19.8% of Atai Beckley shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Axsome Therapeutics beats Atai Beckley on 10 of the 16 factors compared between the two stocks.

How does Atai Beckley compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Atai Beckley (NASDAQ:ATAI) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Crinetics Pharmaceuticals has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

In the previous week, Crinetics Pharmaceuticals had 1 more articles in the media than Atai Beckley. MarketBeat recorded 1 mentions for Crinetics Pharmaceuticals and 0 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.25 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Neutral
Atai Beckley	Neutral

Crinetics Pharmaceuticals currently has a consensus price target of $83.44, indicating a potential downside of 1.77%. Atai Beckley has a consensus price target of $10.56, indicating a potential upside of 43.62%. Given Atai Beckley's higher possible upside, analysts plainly believe Atai Beckley is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 19.8% of Atai Beckley shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Crinetics Pharmaceuticals has a net margin of -1,189.88% compared to Atai Beckley's net margin of -14,938.36%. Crinetics Pharmaceuticals' return on equity of -44.22% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Atai Beckley	-14,938.36%	-88.30%	-58.88%

Crinetics Pharmaceuticals has higher revenue and earnings than Atai Beckley. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A

Summary

Crinetics Pharmaceuticals beats Atai Beckley on 10 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Belite Bio?

Atai Beckley (NASDAQ:ATAI) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

In the previous week, Belite Bio had 5 more articles in the media than Atai Beckley. MarketBeat recorded 5 mentions for Belite Bio and 0 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.25 beat Belite Bio's score of 0.20 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Overall Sentiment
Atai Beckley	Neutral
Belite Bio	Neutral

Belite Bio has lower revenue, but higher earnings than Atai Beckley. Belite Bio is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Atai Beckley presently has a consensus target price of $10.56, indicating a potential upside of 43.62%. Belite Bio has a consensus target price of $218.73, indicating a potential upside of 37.08%. Given Atai Beckley's higher probable upside, research analysts clearly believe Atai Beckley is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 19.8% of Atai Beckley shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Atai Beckley has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market.

Belite Bio has a net margin of 0.00% compared to Atai Beckley's net margin of -14,938.36%. Belite Bio's return on equity of -11.84% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Belite Bio	N/A	-11.84%	-11.62%

Summary

Atai Beckley beats Belite Bio on 9 of the 16 factors compared between the two stocks.

How does Atai Beckley compare to Lantheus?

Atai Beckley (NASDAQ:ATAI) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Atai Beckley currently has a consensus target price of $10.56, indicating a potential upside of 43.62%. Lantheus has a consensus target price of $108.11, indicating a potential upside of 8.15%. Given Atai Beckley's higher possible upside, equities research analysts plainly believe Atai Beckley is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Lantheus had 9 more articles in the media than Atai Beckley. MarketBeat recorded 9 mentions for Lantheus and 0 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.25 beat Lantheus' score of 0.24 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Overall Sentiment
Atai Beckley	Neutral
Lantheus	Neutral

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 19.8% of Atai Beckley shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lantheus has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.14

Atai Beckley has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Lantheus has a net margin of 17.69% compared to Atai Beckley's net margin of -14,938.36%. Lantheus' return on equity of 28.10% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Lantheus	17.69%	28.10%	14.35%

Summary

Lantheus beats Atai Beckley on 11 of the 17 factors compared between the two stocks.

Get Atai Beckley News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATAI vs. The Competition

Export

Metric	Atai Beckley	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.73B	$12.24B	$7.16B	$13.28B
Dividend Yield	N/A	2.64%	2.54%	17.32%
P/E Ratio	-3.37	799.70	275.66	26.04
Price / Sales	666.46	752.92	609.46	91.89
Price / Cash	N/A	86.66	78.87	52.62
Price / Book	10.65	10.46	10.93	6.31
Net Income	-$660.05M	$2.84B	$3.51B	$362.16M

Atai Beckley Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATAI Atai Beckley	2.7326 of 5 stars	$7.35 flat	$10.56 +43.6%	N/A	$2.73B	$4.09M	N/A	80
RDY Dr. Reddy's Laboratories	3.4586 of 5 stars	$12.52 +2.2%	N/A	-12.9%	$10.22B	$3.58B	28.44	27,527	Analyst Upgrade
AXSM Axsome Therapeutics	3.4425 of 5 stars	$193.89 -0.6%	$271.65 +40.1%	+49.4%	$10.22B	$638.50M	N/A	925	News Coverage Analyst Forecast
CRNX Crinetics Pharmaceuticals	0.8398 of 5 stars	$84.95 flat	$83.90 -1.2%	N/A	$9.01B	$7.70M	N/A	210
BLTE Belite Bio	3.3269 of 5 stars	$165.93 -0.8%	$218.73 +31.8%	+115.4%	$6.74B	N/A	N/A	41

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATAI) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atai Beckley (ATAI) Competitors

ATAI vs. RDY, AXSM, CRNX, BLTE, and LNTH

How does Atai Beckley compare to Dr. Reddy's Laboratories?

Summary

How does Atai Beckley compare to Axsome Therapeutics?

Summary

How does Atai Beckley compare to Crinetics Pharmaceuticals?

Summary

How does Atai Beckley compare to Belite Bio?

Summary

How does Atai Beckley compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atai Beckley (ATAI) Competitors

ATAI vs. RDY, AXSM, CRNX, BLTE, and LNTH

How does Atai Beckley compare to Dr. Reddy's Laboratories?

Which has more volatility and risk, RDY or ATAI?

Does the media favor RDY or ATAI?

Do analysts prefer RDY or ATAI?

Is RDY or ATAI more profitable?

Do institutionals & insiders have more ownership in RDY or ATAI?

Which has stronger earnings & valuation, RDY or ATAI?

Summary

How does Atai Beckley compare to Axsome Therapeutics?

Which has more volatility and risk, AXSM or ATAI?

Do analysts recommend AXSM or ATAI?

Is AXSM or ATAI more profitable?

Which has preferable valuation & earnings, AXSM or ATAI?

Does the media refer more to AXSM or ATAI?

Do insiders and institutionals have more ownership in AXSM or ATAI?

Summary

How does Atai Beckley compare to Crinetics Pharmaceuticals?

Which has more risk and volatility, CRNX or ATAI?

Does the media refer more to CRNX or ATAI?

Do analysts prefer CRNX or ATAI?

Do insiders and institutionals have more ownership in CRNX or ATAI?

Is CRNX or ATAI more profitable?

Which has preferable earnings and valuation, CRNX or ATAI?

Summary

How does Atai Beckley compare to Belite Bio?

Does the media refer more to ATAI or BLTE?

Which has stronger valuation and earnings, ATAI or BLTE?

Do analysts prefer ATAI or BLTE?

Do insiders & institutionals have more ownership in ATAI or BLTE?

Which has more risk & volatility, ATAI or BLTE?

Is ATAI or BLTE more profitable?

Summary

How does Atai Beckley compare to Lantheus?

Do analysts recommend ATAI or LNTH?

Does the media prefer ATAI or LNTH?

Do insiders & institutionals have more ownership in ATAI or LNTH?

Which has better earnings and valuation, ATAI or LNTH?

Which has more volatility & risk, ATAI or LNTH?

Is ATAI or LNTH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools